Warning letter
RXQ Compounding LLC: warning letter of May 19, 2016
FDA warning letter 491670 · Cincinnati District Office
Key facts
| Reference number | 491670 |
|---|---|
| Company | RXQ Compounding LLC |
| Subject | Unapproved New Drug/Compounding/Misbranding/Adulterated |
| Issue date | May 19, 2016 |
| Posted date | Jun 7, 2016 |
| Issuing office | Cincinnati District Office |
| Product type | Drugs |
| CFR sections cited | 201.115, 200.10(b), 211.22(c), 211.42(c)(10)(iv), 211.42(c)(10)(vi), 211.113(b), 211.167(a), 210.1(b) |
| Inspection city | Albany |
| Inspection ZIP | 45710 |
| Inspection start date | Aug 24, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: